Accepted Articles
Back to the articles list |
Back to browse issues page
Research code: 1
Ethics code: IR.GUMS.REC.1398.057
1- Department of Pharmaceutical, Biotechnology and Nuclear Pharmacy, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran
2- Department of Radiation Oncology,Gi Cancer Screening and Prevention Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
3- Student Research Committee, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran
2- Department of Radiation Oncology,Gi Cancer Screening and Prevention Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
3- Student Research Committee, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran
Abstract: (311 Views)
Background: Radiotherapy plays a crucial role in cancer treatment; however, a significant challenge is the resistance of cancer cells to radiation, as well as the adverse effects that ionizing radiation can have on adjacent healthy cells.
Objective: This study aimed to assess the radioprotective properties of the drug combination of rosuvastatin and meloxicam against the genetic damage induced by ionizing radiation in healthy human lymphocytes, as well as their radiosensitizing effects on human leukemia HL-60 cells by micronucleus test.
Methods: Lymphocytes were isolated from three healthy volunteers and leukemia cells treated with concentrations of 1,2,10 and 20 μm of rosuvastatin and 5,10,50 and 100 μm of meloxicam, both individually and in a 1:5 combination ratio, before being exposed to ionizing radiation at a dose of 1.5 Gy. The effects were measured using the micronucleus assay.
Results: Key outcomes from the combined treatment of rosuvastatin and meloxicam revealed a dose-dependent decrease in micronucleus formation. Notably, a combination of 20 μM rosuvastatin and 100 μM meloxicam demonstrated significant radioprotective effects in healthy lymphocytes. Treatments with either drug alone did not alter the genotoxicity of the leukemia cells, yet their combinations of 10 μM rosuvastatin and 50 μM meloxicam or 20 μM rosuvastatin and 100 μM meloxicam resulted in mean micronucleus frequencies of 17.53 ± 0.40 and 19.27 ± 0.50, respectively, both significantly exceeding that of the X-ray control group.
Conclusion: The beneficial dual effects of combining rosuvastatin and meloxicam in both leukemia cancer cells and normal cells may present a promising strategy for enhancing the efficacy of radiotherapy in cancer patients.
Objective: This study aimed to assess the radioprotective properties of the drug combination of rosuvastatin and meloxicam against the genetic damage induced by ionizing radiation in healthy human lymphocytes, as well as their radiosensitizing effects on human leukemia HL-60 cells by micronucleus test.
Methods: Lymphocytes were isolated from three healthy volunteers and leukemia cells treated with concentrations of 1,2,10 and 20 μm of rosuvastatin and 5,10,50 and 100 μm of meloxicam, both individually and in a 1:5 combination ratio, before being exposed to ionizing radiation at a dose of 1.5 Gy. The effects were measured using the micronucleus assay.
Results: Key outcomes from the combined treatment of rosuvastatin and meloxicam revealed a dose-dependent decrease in micronucleus formation. Notably, a combination of 20 μM rosuvastatin and 100 μM meloxicam demonstrated significant radioprotective effects in healthy lymphocytes. Treatments with either drug alone did not alter the genotoxicity of the leukemia cells, yet their combinations of 10 μM rosuvastatin and 50 μM meloxicam or 20 μM rosuvastatin and 100 μM meloxicam resulted in mean micronucleus frequencies of 17.53 ± 0.40 and 19.27 ± 0.50, respectively, both significantly exceeding that of the X-ray control group.
Conclusion: The beneficial dual effects of combining rosuvastatin and meloxicam in both leukemia cancer cells and normal cells may present a promising strategy for enhancing the efficacy of radiotherapy in cancer patients.
Keywords: Ionizing radiation, leukemia, radiosensitizer, radioprotector, human lymphocyte, micronucleus
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the
Creative Commons Attribution License (CC-By-NC),which permits use, distribution, and reproduction in any medium,
provided the original work is properly cited and is not used forcommercial purposes.
Contact Information
